These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21714599)

  • 1. New clinical concepts after the ONTARGET trial.
    Ruilope LM; Segura J; Zamorano JL
    Expert Rev Cardiovasc Ther; 2011 Jun; 9(6):685-9. PubMed ID: 21714599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular protection: a breakthrough for high-risk patients?
    Ferrari R
    J Hypertens Suppl; 2009 Jul; 27(5):S37-40. PubMed ID: 19587554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
    Yu LT; Zhu J; Tan HQ; Wang GG; Teo KK; Liu LS
    Chin Med J (Engl); 2011 Jun; 124(12):1763-8. PubMed ID: 21740829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
    Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL;
    Am J Cardiol; 2009 Dec; 104(11):1484-9. PubMed ID: 19932779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?
    Weber M
    J Hypertens Suppl; 2009 Jul; 27(5):S9-14. PubMed ID: 19587555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for double renin-angiotensin-aldosterone system blockade.
    Unger T; Stoppelhaar M
    Am J Cardiol; 2007 Aug; 100(3A):25J-31J. PubMed ID: 17666194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ONTARGET/TRANSCEND Trial Programme: baseline data.
    Sleight P
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
    Böhm M; Baumhäkel M; Mahfoud F; Werner C
    Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.
    Zimmermann M; Unger T
    Expert Opin Pharmacother; 2004 May; 5(5):1201-8. PubMed ID: 15155118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focus on the ONTARGET results.
    Elliott HL
    J Hypertens Suppl; 2009 Jun; 27(2):S8-S10. PubMed ID: 19491625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
    MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381
    [No Abstract]   [Full Text] [Related]  

  • 13. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk.
    Liebson PR; Amsterdam EA
    Prev Cardiol; 2009; 12(1):43-50. PubMed ID: 19301691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
    Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K
    Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
    [No Abstract]   [Full Text] [Related]  

  • 16. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
    Cohn JN
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
    Böhm M; Baumhäkel M; Teo K; Sleight P; Probstfield J; Gao P; Mann JF; Diaz R; Dagenais GR; Jennings GL; Liu L; Jansky P; Yusuf S;
    Circulation; 2010 Mar; 121(12):1439-46. PubMed ID: 20231536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.
    Sleight P
    J Hypertens Suppl; 2009 Jul; 27(5):S23-9. PubMed ID: 19587551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.
    Mancia G; Unger T; Zanchetti A
    J Hypertens Suppl; 2009 Jul; 27(5):S1. PubMed ID: 19587549
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.